New US tests must detect subtype-O
This article was originally published in Clinica
The US FDA says any new kits submitted for approval will now be expected to detect subtype-O reliably, following the first CDC report of a case in the US. The infection was detected in a woman who had repeatedly tested negative for HIV-1 but who had symptoms of AIDS. It was identified after PCR with group-O primers. The patient, who has lived in the US since 1994, is believed to have acquired the infection in West Central Africa - like all but one or two of the handful of cases detected in Europe.
You may also be interested in...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.